Nuclear PTEN levels and G 2 progression in melanoma cells

Melanoma Research

Volumn 19, Issue 4, 2009, Pages 203-210

  Jacob, Abraham I ^a   Romigh, Todd ^a   Waite, Kristin A ^a,b   Eng, Charis ^a,b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

G 2 M arrest and progression; Nuclear expression; PTEN

Indexed keywords

CYCLIN DEPENDENT KINASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN;

ARTICLE; CELL COMPARTMENTALIZATION; CELL CYCLE; CELL CYCLE G2 PHASE; CELL NUCLEUS; CYTOPLASM; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MELANOMA; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; PROTEIN SYNTHESIS; RNA INTERFERENCE; TUMOR CELL LINE;

CDC2 PROTEIN KINASE; CELL COMPARTMENTATION; CELL CYCLE; CELL LINE, TUMOR; CELL NUCLEUS; CYTOPLASM; DOWN-REGULATION; G2 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN BIOSYNTHESIS; PTEN PHOSPHOHYDROLASE; RNA INTERFERENCE;

EID: 70349921188     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32832ccd6e     Document Type: Article

References (45)

1. Eng C. PTEN: one gene, many syndromes. Hum Mutat 2003; 22:183-198. (Pubitemid 37071635)
2. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 16:64-67. (Pubitemid 27198157)
3. Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RJ, et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 1997; 16:333-334.
4. Eng C, Thiele H, Zhou XP, Gorlin RJ, Hennekam RC, Winter RM. PTEN mutations and Proteus syndrome. Lancet 2001; 358:2079-2080.
5. Zhou XP, Marsh DJ, Hampel H, Mulliken JB, Gimm O, Eng C. Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis. Hum Mol Genet 2000; 9:765-768. (Pubitemid 30162760)
6. Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 1999; 91:1922-1932.
7. Bonneau D, Longy M. Mutations of the human PTEN gene. Hum Mutat 2000; 16:109-122. (Pubitemid 30604900)
8. Zbuk KM, Eng C. Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer 2007; 7:35-45. (Pubitemid 46020845)
9. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000; 92:924-930.
10. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Eng C. Changes in endometrial PTEN expression throughout the human menstrual cycle. J Clin Endocrinol Metab 2000; 85:2334-2338. (Pubitemid 32269265)
11. Boni R, Vortmeyer AO, Burg G, Hofbauer G, Zhuang Z. The PTEN tumour suppressor gene and malignant melanoma. Melanoma Res 1998; 8:300-302. (Pubitemid 28442560)
12. Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 1997; 57:5221-5225. (Pubitemid 27516352)
13. Tsao H, Zhang X, Benoit E, Haluska FG. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 1998; 16:3397-3402. (Pubitemid 28349682)
14. Reifenberger J, Wolter M, Bostrom J, Buschges R, Schulte KW, Megahed M, et al. Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas. Virchows Arch 2000; 436: 487-493. (Pubitemid 30312165)
15. Zhou XP, Gimm O, Hampel H, Niemann T, Walker MJ, Eng C. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 2000; 157:1123-1128.
16. Abdel-Rahman MH, Yang Y, Zhou XP, Craig EL, Davidorf FH, Eng C. High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. J Clin Oncol 2006; 24:288-295. (Pubitemid 46622057)
17. Gimm O, Perren A,Weng LP, Marsh DJ, Yeh JJ, Ziebold U, et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol 2000; 156:1693-1700. (Pubitemid 30646707)
18. Ginn-Pease ME, Eng C. Increased nuclear phosphatase and tensin homologue deleted on chromosome 10 is associated with G0-G1 in MCF-7 cells. Cancer Res 2003; 63:282-286. (Pubitemid 36152480)
19. Perren A, Komminoth P, Saremaslani P, Matter C, Feurer S, Lees JA, et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol 2000; 157:1097-1103.
20. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7:606-619. (Pubitemid 44100518)
21. Gu J, Tamura M, Yamada KM. Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol 1998; 143:1375-1383. (Pubitemid 28559837)
22. Maehama T. PTEN: its deregulation and tumorigenesis. Biol Pharm Bull 2007; 30:1624-1627. (Pubitemid 47403234)
23. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998; 273:13375-13378. (Pubitemid 28268370)
24. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 2000; 20:8969-8982. (Pubitemid 32245927)
25. Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene 2003; 22:3113-3122. (Pubitemid 36713763)
26. Chung JH, Eng C. Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis. Cancer Res 2005; 65: 8096-8100. (Pubitemid 41330571)
27. Chung JH, Ostrowski MC, Romigh T, Minaguchi T, Waite KA, Eng C. The ERK1/2 pathway modulates nuclear PTEN-mediated cell cycle arrest by cyclin D1 transcriptional regulation. Hum Mol Genet 2006; 15: 2553-2559. (Pubitemid 44288685)
28. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007; 128:157-170. (Pubitemid 46048887)
29. Liu JL, Sheng X, Hortobagyi ZK, Mao Z, Gallick GE, Yung WK. Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Mol Cell Biol 2005; 25:6211-6224. (Pubitemid 40946569)
30. Whiteman DC, Zhou XP, Cummings MC, Pavey S, Hayward NK, Eng C. Nuclear PTEN expression and clinicopathologic features in a populationbased series of primary cutaneous melanoma. Int J Cancer 2002; 99:63-67. (Pubitemid 34273199)
31. Taylor WR. FACS-based detection of phosphorylated histone H3 for the quantitation of mitotic cells. Methods Mol Biol 2004; 281:293-299.
32. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001; 20:1803-1815. (Pubitemid 32458690)
33. Pines J. Cyclins and cyclin-dependent kinases: a biochemical view. Biochem J 1995; 308 (Pt 3):697-711.
34. Chada S, Bocangel D, Ramesh R, Grimm EA, Mumm JB, Mhashilkar AM, et al. mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer. Mol Ther 2005; 11:724-733. (Pubitemid 40567977)
35. Dupont J, Renou JP, Shani M, Hennighausen L, LeRoith D. PTEN overexpression suppresses proliferation and differentiation and enhances apoptosis of the mouse mammary epithelium. J Clin Invest 2002; 110:815-825.
36. Waite KA, Sinden MR, Eng C. Phytoestrogen exposure elevates PTEN levels. Hum Mol Genet 2005; 14:1457-1463. (Pubitemid 40823455)
37. Fang J, Ding M, Yang L, Liu LZ, Jiang BH. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal 2007; 19:2487-2497. (Pubitemid 47531929)
38. Welch PJ,Wang JY. Coordinated synthesis and degradation of cdc2 in the mammalian cell cycle. Proc Natl Acad Sci U S A 1992; 89:3093-3097.
39. Tolkacheva T, Boddapati M, Sanfiz A, Tsuchida K, Kimmelman AC, Chan AM. Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383. Cancer Res 2001; 61:4985-4989. (Pubitemid 32681524)
40. Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem 2001; 276:993-998. (Pubitemid 32096519)
41. Nicolson GL, Nawa A, Toh Y, Taniguchi S, Nishimori K, Moustafa A. Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: role in epithelial cancer cell invasion, proliferation and nuclear regulation. Clin Exp Metastasis 2003; 20:19-24. (Pubitemid 36308132)
42. Forget MA, Turcotte S, Beauseigle D, Godin-Ethier J, Pelletier S, Martin J, et al. The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types. Br J Cancer 2007; 96:646-653.
43. Kimura F, Watanabe J, Hata H, Fujisawa T, Kamata Y, Nishimura Y, et al. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. J Cancer Res Clin Oncol 2004; 130:161-168. (Pubitemid 38392349)
44. Kappes H, Goemann C, Bamberger AM, Loning T, Milde-Langosch K. PTEN expression in breast and endometrial cancer: correlations with steroid hormone receptor status. Pathobiology 2001; 69:136-142. (Pubitemid 34212084)
45. Stoica A, Hoffman M, Marta L, Voiculetz N. Estradiol and progesterone receptors in human cutaneous melanoma. Neoplasma 1991; 38:137-145.